Influenza defense: Expanding our arsenal with peptide antivirals

Future Virology

Volumn 2, Issue 3, 2007, Pages 231-233

  Jones, Jeremy ^a   Brandt, Curtis R ^a   Schultz Cherry, Stacey ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ENFURVITIDE; INFLUENZA VACCINE; OSELTAMIVIR; RELENSA; RIMANTADINE; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; EDITORIAL; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFLUENZA; INFLUENZA VIRUS A; MEDICAL RESEARCH; MORBIDITY; MORTALITY; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS INHIBITION; VIRUS MUTATION; VIRUS VIRULENCE;

EID: 34249274938     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.3.231     Document Type: Editorial

References (24)

1. Cox RJ, Brokstad KA, Ogra P: Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59(1), 1-15 (2004).
2. Stiver G: The treatment of influenza with antiviral drugs. CAMJ 168(1), 49-56 (2003).
3. Horimoto T, Kawaoka Y: Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3(8), 591-600 (2005).
4. Nguyen-Van-Tam JS, Hampson AW: The epidemiology and clinical impact of pandemic influenza. Vaccine 21(16), 1762-1768 (2003).
5. Claas EC, Osterhaus AD, van Beek R et al.: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet, 351(9101), 472-477 (1998).
6. De Clercq E: Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5(12), 1015-1025 (2006).
7. Yen HL, Herlocher LM, Hoffmann E et al.: Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49(10), 4075-4084 (2005).
8. Izadpanah A, Gallo RL: Antimicrobial peptides. J. Am. Acad. Dermatol. 52(3 Pt 1), 381-390 (2005).
9. Koczulla AR, Bals R: Antimicrobial peptides: current status and therapeutic potential. Drugs 63(4), 389-406 (2003).
10. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM: Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr. Eye Res. 30(5), 385-394 (2005).
11. Klotman ME, Chang TL: Defensins in innate antiviral immunity. Nat. Rev. Immunol. 6(6), 447-456 (2006).
12. Pastey MK, Gower TL, Spearman PW, Crowe JE Jr, Graham BS: A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nat. Med. 6(1), 35-40 (2000).
13. Fung HB, Guo Y: Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin. Ther. 26(3), 352-378 (2004).
14. Okazaki K, Kida H: A synthetic peptide from a heptad repeat region of herpesvirus glycoprotein B inhibits virus replication. J. Gen. Virol. 85(Pt 8), 2131-2137 (2004).
15. Bultmann H, Busse JS, Brandt CR: Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1. J. Virol. 75(6), 2634-2645 (2001).
16. Bultmann H, Brandt CR: Peptides containing membrane-transiting motifs inhibit virus entry. J. Biol. Chem. 277(39), 36018-36023 (2002).
17. Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S: Inhibition of influenza vinis infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 80(24), 11960-11967 (2006).
18. Hayden FG: Perspectives on antiviral use during pandemic influenza. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356(1416), 1877-1884 (2001).
19. Barnett DJ, Balicer RD, Lucey DR et al.: A systematic analytic approach to pandemic influenza preparedness planning. PLoS Med. 2(12), e359 (2005).
20. Judd AK, Sanchez A, Bucher DJ, Huffman JH, Bailey K, Sidwell RW: In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrob. Agents Chemother. 41(3), 687-692 (1997).
21. Collier NC, Knox K, Schlesinger MJ: Inhibition of influenza virus formation by a peptide that corresponds to sequences in the cytoplasmic domain of the hemagglutinin. Virology 183(2), 769-772 (1991).
22. Malakhov MP, Aschenbrenner LM, Smee DF et al.: Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 50(4), 1470-1479 (2006).
23. Hazrati E, Galen B, Lu W et al.: Human α- and β-defensins block multiple steps in herpes simplex virus infection. J. Immunol. 177(12), 8658-8666 (2006).
24. Matthews T, Salgo, M, Greenberg M, Chung J, DeMasi R, Bolognesi D: Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3(3), 215-225 (2004).